Elevated α-Synuclein Aggregate Levels in the Urine of Patients with Isolated REM Sleep Behavior Disorder and Parkinson's Disease
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

Elevated α-Synuclein Aggregate Levels in the Urine of Patients with Isolated REM Sleep Behavior Disorder and Parkinson's Disease

New research is shedding light on a potential breakthrough for diagnosing Parkinson's disease (PD). A study using surface-based fluorescence intensity distribution analysis (sFIDA) found that α-synuclein aggregates, commonly associated with PD, can be detected in urine samples.

Read More
Ultraprocessed Foods Linked to Early Symptoms of Parkinson’s
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

Ultraprocessed Foods Linked to Early Symptoms of Parkinson’s

A recent study of over 42K participants published in Neurology reveals that a diet high in ultraprocessed foods may increase the likelihood of developing early signs of Parkinson’s disease, including probable RBD. Participants who ate the most ultraprocessed foods were 2.5 times more likely to show early symptoms like constipation, reduced smell, and sleep disturbances. While the findings aren’t conclusive, they underscore the importance of diet in brain health.

Read More
REM Sleep Behavior Disorder: How Do We Decide if REM EMG Activity is Excessive?
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

REM Sleep Behavior Disorder: How Do We Decide if REM EMG Activity is Excessive?

NAPS Co-Principal Investigator Dr. Brad Boeve teams up with Dr. Mike Silber, a member of the NAPS Scientific Advisory Board, for an episode on REM sleep behavior disorder (RBD) in the Mayo Clinic Sleep Medicine Podcasts.

The diagnosis of REM sleep behavior disorder needs, in addition to dream enactment behavior, a determination that EMG activity is excessive during REM sleep. But what is excessive? In this podcast, the team discusses how a practicing polysomnographer can make this determination.

Read More
REM Sleep Behavior Disorder (RBD): Personal Perspectives and Research Priorities
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

REM Sleep Behavior Disorder (RBD): Personal Perspectives and Research Priorities

Dr. Carlos Schenck, who, alongside Mark Mahowald, was the first to describe RBD, continues to play an active role in the field, currently serving on the NAPS Scientific Advisory Board. In a recent publication in the Journal of Sleep Research, he reviewed key milestones in RBD and synucleinopathy research and discussed the current research priorities.

Read More
REM Sleep Behavior Disorder: What factors affect risk of progression to Parkinson pathology?
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

REM Sleep Behavior Disorder: What factors affect risk of progression to Parkinson pathology?

NAPS Co-Principal Investigator Dr. Brad Boeve teams up with Dr. Mike Silber, a member of the NAPS Scientific Advisory Board, for an episode on REM sleep behavior disorder (RBD) in the Mayo Clinic Sleep Medicine Podcasts. They explore the connection between RBD and synucleinopathies like Parkinson's disease.

Read More
REM Sleep Behavior Disorder: How near are we to preventing Parkinson’s Disease?
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

REM Sleep Behavior Disorder: How near are we to preventing Parkinson’s Disease?

NAPS Co-Principal Investigator Dr. Brad Boeve teams up with Dr. Mike Silber, a member of the NAPS Scientific Advisory Board, for an episode on REM sleep behavior disorder (RBD) in the Mayo Clinic Sleep Medicine Podcasts. They explore the connection between RBD and synucleinopathies like Parkinson's disease.

Read More